Opinion|Videos|March 19, 2025
Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting
Author(s)Matthew Galsky, MD
An expert discusses how medical professionals are increasingly utilizing circulating tumor DNA (ctDNA) and tissue PD-L1 to guide recommendations for adjuvant immune checkpoint inhibitor (ICI) therapy. ctDNA helps monitor minimal residual disease and early treatment response while tissue PD-L1 status aids in predicting ICI efficacy, optimizing patient treatment plans.
Episodes in this series
Video content above is prompted by the following:
- Are you using ctDNA and/or tissue PD-L1 to guide recommendations for adjuvant ICI and/or to monitor response to adjuvant ICI?
